LeMaitre George W 4

What Happened

George W. LeMaitre, Chairman and CEO of LeMaitre Vascular, reported receiving dividend-equivalent rights that converted into 51.844 share-equivalents on March 26, 2026. These were reported as grant/award acquisitions (derivative securities) at a $0.00 per-share acquisition price — i.e., no cash was paid by the insider. The amounts are small (about 52 shares total) and reflect accrued dividend equivalents tied to previously granted restricted stock units (RSUs) and performance share units (PSUs).

Key Details

• Transaction date: 2026-03-26; Form 4 filed: 2026-03-30 (filed within the normal two-business-day window).
• Individual entries (all acquired as derivative dividend-equivalents at $0.00):
  • 3.392 shares (F1) — accrued on RSU grant 12/12/2022
  • 3.392 shares (F2) — accrued on PSU grant 12/12/2022
  • 5.799 shares (F3) — accrued on RSU grant 12/08/2023
  • 6.949 shares (F4) — accrued on PSU grant 12/08/2023
  • 8.482 shares (F5) — accrued on RSU grant 12/06/2024
  • 9.611 shares (F6) — accrued on PSU grant 12/06/2024
  • 14.219 shares (F7) — accrued on RSU grant 12/10/2025
• Total acquired: 51.844 dividend-equivalent share units; reported value on the Form 4 is $0 because these are non-cash accruals.
• The filing does not indicate additional cash transactions, tax-withholding share-for-fee actions, or sales connected to these accruals.

Context

• These were dividend-equivalent rights that vest proportionately with the underlying RSU/PSU awards — effectively the economic equivalent of receiving additional shares tied to prior equity grants. They are derivative awards (code A), not open-market purchases or sales.
• Because this is an award/vesting event with no cash outlay and a small share count, it is generally routine compensation reporting rather than a directional insider buy/sell signal.